CreaGen positions itself for further growth by expanding its current products’ business to better meet the growing demands of the industry to obtain difficult to find and make organic and organometallic compounds.

WOBURN, MA — CreaGen Biosciences is a specialty drug discovery chemistry service company (“CreaGen”), today announced its next step in meeting the growing demands of the drug discovery industry by acquiring Prime Organics’ Catalogue Business. Prime Organics closed its doors after almost 20 years of business this May. Acquiring Prime’s Catalogue Business, demonstrates CreaGen’s continued evolution to respond to the demands of the industry in turn response to the industry’s need to find it extremely challenging to obtain difficult to find and complex organic and organometallic compounds to make. CreaGen will continue to provide their clients their full range of drug discovery chemistry expertise.

“It has not been easy to close our doors after all these years. It has been a labor of ‘love of chemistry.’ However, we are thrilled to be handing over this part of our business to CreaGen, especially given their extensive experience in medicinal chemistry and drug discovery,” said Joe Kremsky, Ph.D., President and CEO, Prime Organics. “This will remain a partnership enabling us to share brainpower, and knowhow in organic synthesis and purification while tapping into CreaGen’s expansive facilities for this continued and often requested service.”

“We are excited to take over this part of Prime’s business and to have this special opportunity to grow this part of our existing business. We are confident that this service will continue to be in demand and our expert team of chemists can even expand our product line further,” said Raj Rajur, Ph.D., Chairman and CEO of CreaGen Biosciences. “This addition to our CreaGen family: CreaGen BioSciences, CreaGen Chemistry Incubator and CreaGen Discovery, enables us to play a strategic role in drug discovery and fueling the drug pipeline.”

About CreaGen Biosciences
CreaGen Biosciences is a specialty drug discovery chemistry service company that provides high quality research support to biotech and pharmaceutical companies. The company’s discovery research service engine, Integrated Chemistry Operating System (ICOS™), helps transform research ideas into innovative medicines, serving as a de facto medicinal chemistry facility for moving concepts to the clinic. CreaGen’s scientists are highly skilled with extensive experience in a broad range of therapeutic areas, offering partners an opportunity to expand their core business on a fast track while significantly reducing overhead costs. In addition, CreaGen’s Chemistry Incubator Division offers innovators a collaborative place to launch, incubate and grow their emerging life science companies. Recognized as the preferred contract research organization to top pharmaceutical and emerging companies and the only regional incubator dedicated to chemistry, CreaGen offers a unique and flexible chemistry experience that is enjoyed by more than 50 companies worldwide and a number of emerging biotechs. For more information, visit www.creageninc.com.

Media contact:
Shelley Amster
978-239-1468
Email Contact :shelley@shelleyco.com